Plasma magnesium levels and treatment outcome in depressed patients

Camardese, Giovanni; Risio, Luisa De; Pizi, Giusy; Mattioli, Bruna; Buccelletti, Francesco; Serrani, Riccardo; Leone, Beniamino; Sgambato, Alessandro; Bria, Pietro; Janiri, Luigi

doi:10.1179/1476830512y.0000000002

Cited by 25 publications

(27 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In contrast to our findings Camardese et al reported low plasma Mg 2þ levels to be predictive for worse response to standard antidepressant treatment (Camardese et al, 2012). Patients in their study were off antidepressant medication for at least 1 week and not hospitalized, i.e.…”

Section: Discussioncontrasting

confidence: 85%

Target-based biomarker selection – Mineralocorticoid receptor-related biomarkers and treatment outcome in major depression

Büttner

Ježová

Greene

et al. 2015

Journal of Psychiatric Research

View full text Add to dashboard Cite

Section: Discussioncontrasting

confidence: 85%

Target-based biomarker selection – Mineralocorticoid receptor-related biomarkers and treatment outcome in major depression

Büttner

Ježová

Greene

et al. 2015

Journal of Psychiatric Research

View full text Add to dashboard Cite

“…Since the mechanism of magnesium’s role in depression is still not clear, it is difficult to say why this relationship with antidepressants may exist. In a sample of treatment resistant depressed patients with normal magnesium levels, those with high normal magnesium levels had a more robust response to antidepressants [29]. In another study, severity of depression correlated with reduced intracellular magnesium, and that cellular levels normalized after successful treatment with antidepressants [30].…”

Section: Discussionmentioning

confidence: 99%

Role of magnesium supplementation in the treatment of depression: A randomized clinical trial

et al. 2017

View full text Add to dashboard Cite

Current treatment options for depression are limited by efficacy, cost, availability, side effects, and acceptability to patients. Several studies have looked at the association between magnesium and depression, yet its role in symptom management is unclear. The objective of this trial was to test whether supplementation with over-the-counter magnesium chloride improves symptoms of depression. An open-label, blocked, randomized, cross-over trial was carried out in outpatient primary care clinics on 126 adults (mean age 52; 38% male) diagnosed with and currently experiencing mild-to-moderate symptoms with Patient Health Questionnaire-9 (PHQ-9) scores of 5–19. The intervention was 6 weeks of active treatment (248 mg of elemental magnesium per day) compared to 6 weeks of control (no treatment). Assessments of depression symptoms were completed at bi-weekly phone calls. The primary outcome was the net difference in the change in depression symptoms from baseline to the end of each treatment period. Secondary outcomes included changes in anxiety symptoms as well as adherence to the supplement regimen, appearance of adverse effects, and intention to use magnesium supplements in the future. Between June 2015 and May 2016, 112 participants provided analyzable data. Consumption of magnesium chloride for 6 weeks resulted in a clinically significant net improvement in PHQ-9 scores of -6.0 points (CI -7.9, -4.2; P<0.001) and net improvement in Generalized Anxiety Disorders-7 scores of -4.5 points (CI -6.6, -2.4; P<0.001). Average adherence was 83% by pill count. The supplements were well tolerated and 61% of participants reported they would use magnesium in the future. Similar effects were observed regardless of age, gender, baseline severity of depression, baseline magnesium level, or use of antidepressant treatments. Effects were observed within two weeks. Magnesium is effective for mild-to-moderate depression in adults. It works quickly and is well tolerated without the need for close monitoring for toxicity.

show abstract

“…One of the most important prevention-related aspects is the influence of nutritional factors. It has been proved that Mg deficiency may play an important role in the development of depression and mood disorders [8–10]. …”

Section: Introductionmentioning

confidence: 99%

The Severity of Depressive Symptoms vs. Serum Mg and Zn Levels in Postmenopausal Women

Stanisławska

Szkup-Jabłońska

Jurczak

et al. 2013

Biol Trace Elem Res

View full text Add to dashboard Cite

The aim of this study was to assess the severity of depressive symptoms in postmenopausal women, depending on serum Mg and Zn levels. The study involved 171 postmenopausal women from Poland, who were not using menopausal hormone therapy (MHT). The intensity of depressive symptoms was evaluated using a standard research technique, the Beck Depression Inventory (BDI). The plasma Mg and Zn concentrations were measured. Depressive symptoms of different severity levels were diagnosed in 36.8 % of the women. The mean serum Mg level was 1.53 ± 0.28 mg/dL, and Zn level was 72 ±14 μg/dL. The women with higher serum Mg and Zn levels had less depressive symptoms, and this observation is a precious information which can be used when planning depressive disorder prevention programmes.

show abstract

Plasma magnesium levels and treatment outcome in depressed patients

Cited by 25 publications

References 33 publications

Target-based biomarker selection – Mineralocorticoid receptor-related biomarkers and treatment outcome in major depression

Target-based biomarker selection – Mineralocorticoid receptor-related biomarkers and treatment outcome in major depression

Role of magnesium supplementation in the treatment of depression: A randomized clinical trial

The Severity of Depressive Symptoms vs. Serum Mg and Zn Levels in Postmenopausal Women

Contact Info

Product

Resources

About